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Background: The study investigated the effectiveness of dexamethasone injections for reducing the
occurrence of postextubation airway obstruction (PEAO).
Methods: One hundred and thirty-eight patients who were intubated for  48 hours with a cuff-leak
volume (CLV) < 110 mL were treated with low-dose dexamethasone (5 mg; n ¼ 41), high-dose dexa-
methasone (10 mg; n ¼ 42), or placebo (normal saline; n ¼ 43) injection every 6 hours for a total of four
doses on the day preceding extubation. CLV was measured before the ﬁrst injection, 1 hour after each
injection, and 24 hours after the fourth injection. Extubation was performed 24 hours after the last in-
jection. PEAO was recorded within 48 hours postextubation.
Results: Administration of dexamethasone resulted in a signiﬁcant increase in absolute CLV and change
of CLV relative to baseline tidal volume occurred (p < 0.05). However, there was no signiﬁcant difference
between the low- and high-dose dexamethasone groups. The incidence of PEAO was 7.1% in the high-
dose group, 9.8% in the low-dose group, and 30.2% in the placebo group. The incidence of PEAO
differed signiﬁcantly between the dexamethasone groups and the placebo group (p ¼ 0.001). There was
no signiﬁcant difference in the reintubation rates among the high-dose group (2.1%, 1/42), the low-dose
group (2.4%, 1/41), and the placebo group (4.7%, 2/43; p ¼ 0.79).
Conclusion: Prophylactic administration of multiple low-dose dexamethasone is sufﬁcient for reducing
the incidence of PEAO in high-risk patients.
Copyright © 2016, Taiwan Society of Geriatric Emergency & Critical Care Medicine. Published by Elsevier
Taiwan LLC. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).1. Introduction
Postextubation airway obstruction (PEAO) is a serious compli-
cation for intubated patients, which frequently leads to reintuba-
tion and a prolongation of intensive care. Previous reports indicated
that 2e40% of intensive care unit (ICU) patients develop PEAO
requiring reintubation1,2. Mortality associated with reintubation
has been estimated to be as high as 30e40%1e4. Several factors have
been correlated with the development of PEAO, including age, fe-
male sex, an elevated Acute Physiology Score II, trauma related tos of interest to declare.
f Pulmonary and Critical Care
Memorial Hospital, Number
4, Taiwan.
tric Emergency & Critical Care Med
es/by-nc-nd/4.0/).endotracheal intubation, excessive tube size, unnecessary tube
mobility, increased pressure in cuff, frequent tracheal aspiration,
infection, arterial hypotension, and a prolonged period of
intubation5.
Laryngotracheal injury associated with intubation can induce
narrowing of the airway due to edema of the glottis, leading to
increased risk of PEAO and respiratory distress. The sequelae
increasedmorbidity andmortality5,6. The difﬁculty in establishing a
relationship between laryngotracheal edemamight be partly due to
the presence of an endotracheal tube. In intubated patients, a
positive cuff-leak test has been demonstrated to be a predictor of
laryngotracheal edema in high-risk patients who could develop
PEAO7e11.
There have been some reports on the effectiveness of cortico-
steroid therapy prior to extubation for preventing PEAO12e18. Most
studies employed retrospective analysis of outcomes on subgroupsicine. Published by Elsevier Taiwan LLC. This is an open access article under the CC
C.-Y. Lin et al.12of patients who received steroids during their intubation. More-
over, previous studies regarding the efﬁcacy of prophylactic dexa-
methasone in intubated patients have yielded conﬂicting
results19e22. Indeed, the lack of agreement among reports might be
attributed to variation in patient age, sex, albumin level, disease
severity, setting and duration of endotracheal intubation, dose and
duration of treatment, as well as outcome variables and timing of
observations, level of sedation, and degree of airway manipulation.
Our previous study demonstrated the effectiveness of 5-mg dexa-
methasone to relieve PEAO21. However, we observed no signiﬁcant
difference in the reintubation rate. Therefore we wished to answer
two questions; is it possible to prevent laryngeal edema-induced
complications by increasing the dosage of dexamethasone ther-
apy? Is cuff-leak volume (CLV) associatedwith the reintubation rate
in high-risk patients?
This study evaluated a subset of high-risk patients who had
been intubated for over 48 hours and were undergoing their
extubation in an ICU setting. The study objectives were to deter-
mine if multiple injections of high-dose dexamethasonewere more
effective than low-dose dexamethasone to reduce PEAO in patients
with a CLV less than 110mL, and to evaluate whether an after-effect
(i.e., transient prevention) persisted following the discontinuation
of dexamethasone.
2. Materials and methods
MacKay Memorial Hospital (Taipei, Taiwan) is a tertiary referred
hospital. After approval from the Institutional Research Ethics
Board, this study was performed in the adult medical ICU.
Consecutive patients admitted between 1 April, 2007, and 31
March, 2010, who met the inclusion criteria described below were
included in this study. We obtained informed consent from the
patients prior to enrollment into the trial. All patients recruited in
this study received endotracheal intubation with a high-volume,
low-pressure cuffed tube with an internal diameter of 6.5 mm,
7 mm, 7.5 mm, or 8 mm. Patients exhibiting excessive movement
were sedated or paralyzed during mechanical ventilation (MV).
All patients were older than 18 years andmet all of the following
criteria for weaning: (1) pH  7.3; (2) heart rate  70 bpm and 
130 bpm; (3) fraction of inspired oxygen (FiO2)  60%, partial
pressure of oxygen (PaO2)  60 mmHg, and PaO2/FiO2 ratio  2 00;
(4) rapid and shallow ratio of frequency to tidal volume 105; (5)
temperature  38C for  8 hours; (6) positive end-expiratory
pressure  5 cm H2O; (7) discontinuous use of sedatives 1 hour
before study; (8) minute ventilation  15 L/min; and (9) systolic
blood pressure  80 mmHg in the absence of a vasopressor. Sup-
plemental oxygen was continued to maintain an oxygen saturation
 95% as measured with a pulse oximeter. Exclusion criteria were
either: (1) administration of corticosteroids 7 days prior to extu-
bation; or (2) a history of extubation during the same
hospitalization.
Cuff-leak tests were administered to the patients who required
MV for > 48 hours and who ﬁt the above criteria. Patients were
mechanically ventilated in the volume-assisted control mode using
a Bird 8400 STi ventilator (Bird, Palm Springs, CA, USA) with a tidal
volume of 10 mL/kg of ideal body weight, a respiratory rate of 20
breaths per minute, and a zero positive end-expiratory pressure
during CLV measurement. The balloon cuff was deﬂated and the
expiratory tidal volume was recorded over the next six subsequent
respiratory cycles, with the average of the lowest three values used
for subsequent analyses. The CLV was determined as the difference
in the actual tidal volume before and after cuff deﬂation.
Patients requiring MV for > 48 hours and exhibiting a CLV 
110 mL before planned extubation were included in the trial, as
suggested by previous studies9,10. A respiratory therapist who wasnot involved in the patient's care prepared the study drug and the
identical-looking placebo. She also recorded all data into a
password-protected database. Patients were randomly assigned to
receive an intravenous injection of dexamethasone 5 mg, 10 mg, or
normal saline at an equivalent volume (placebo) per injection. The
medical staff who administered the injections was blinded to the
contents of the injections. On the day before extubation, dexa-
methasonewas administered every 6 hours for a total of four doses.
We measured CLVs before the ﬁrst injection, 1 hour after each in-
jection, and 24 hours after the fourth injection. All patients were
extubated 24 hours after the last injection of dexamethasone or
normal saline.
PEAO (deﬁned as the presence of stridor heard with the aid of a
stethoscope) was recorded if it occurred within 48 hours of extu-
bation. The presence of stridor was an indication for the inhalation
of racemic epinephrine. Patients experiencing respiratory distress
were assigned to receive noninvasive positive-pressure ventilation
by face mask if they failed to respond to two doses of epinephrine
inhalation and exhibited at least two of the following criteria of
respiratory distress: (1) clinical signs suggestive of respiratory-
muscle fatigue or increased respiratory effort (the use of acces-
sory muscles, intercostal retraction, or paradoxical motion of the
abdomen); (2) hypoxemia (deﬁned as an arterial oxygen satura-
tion < 90% or a PaO2 < 80 mmHg with an FiO2 > 50%); (3) a res-
piratory rate > 25 breaths per minute for 2 consecutive hours; and
(4) respiratory acidosis (deﬁned as an arterial pH < 7.35 with a
partial pressure of arterial carbon dioxide > 45 mmHg). Patients
were reintubated and received MV support if they met at least one
of the following criteria: (1) copious secretions that could not be
cleared adequately or that were associated with acidosis, hypox-
emia, or changes in mental status (somnolence, agitation, or dia-
phoresis); (2) lack of improvement in signs of respiratory-muscle
fatigue; (3) hypotension with an systolic blood
pressure < 80 mmHg for > 30 minutes despite adequate volume
challenge; (4) a decrease in oxygen saturation to < 85% despite
using a high FiO2 (a PaO2 < 50 mmHg with an FiO2 > 70%); (5) a
change in mental status rendering the patient unable to tolerate
noninvasive ventilation; (6) a diastolic blood pressure drop of >
20 mmHg; or (7) a pH of < 7.3 with a partial pressure of carbon
dioxide increase of > 15 mmHg (Figure 1).
Statistical analyses were conducted using the SPSS software
package (IBM SPSS Statistics for Windows, version 20.0: IBM Corp.,
Armonk, NY, USA). We conducted univariate analyses of the dexa-
methasone and placebo groups using analysis of variance for
continuous variables and a Pearson Chi-square test for categorical
variables, or Fisher's exact test, as indicated. A p value < 0.05 was
considered statistically signiﬁcant.
3. Results
A total of 588 patients admitted through the ICU received the
cuff-leak test during the study period. Four hundred and ﬁfty pa-
tients were excluded because of self-extubation (n ¼ 9), deterio-
ration (n ¼ 14), or CLV > 100 mL (n ¼ 427). All of the 138 patients
with a CLV less than 110 mL met the inclusion criteria (Figure 2).
These patients were randomly assigned to the high-dose (10 mg)
dexamethasone group (n ¼ 46), the low-dose (5 mg) dexametha-
sone group (n¼ 46), and the placebo group (n¼ 46). Approximately
91% of the patients (n ¼ 126) in this study successfully completed
the course. Therewere no signiﬁcant differences in sex, age, weight,
height, duration of intubation, diameter of the endotracheal tube,
and disease severity among the three groups (Table 1). As shown in
Figures 3 and 4, the patients in the dexamethasone groups had a
signiﬁcant increase in absolute CLV and change of CLV relative to
baseline tidal volume (percentage; p < 0.05). But there was no
Figure 1. Postextubation airway obstruction therapy ﬂowchart. CLV ¼ cuff-leak volume.
Dexamethasone in Preventing Airway Obstruction 13signiﬁcant difference in the absolute CLV and change of CLV relative
to baseline tidal volume (percentage) when comparing the high-
and low-dose dexamethasone groups. The incidence of PEAO was
7.1% (3/42) in the high-dose dexamethasone group, 9.8% (4/41) in
the low-dose dexamethasone group, and 30.2% (13/43) in the pla-
cebo group. PEAO differed signiﬁcantly between the dexametha-
sone groups and the placebo group (p ¼ 0.001). There was no
signiﬁcant difference in the incidence of PEAO between the high-
and low-dose dexamethasone groups (p ¼ 0.67). There was noFigure 2. Study ﬂowchart. CLV ¼ cuff-leaksigniﬁcant difference in the reintubation rates among the high-
dose dexamethasone group (2.1%, 1/42), the low-dose dexameth-
asone group (2.4%, 1/41), and the placebo group (4.7%, 2/43;
p ¼ 0.79).
4. Discussion
Laryngeal edema and the accompanying stridor are common
problems following extubation after prolonged MV. Because thevolume; VT ¼ ventricular tachycardia.
Table 1
Demographic data of the patients.
High-dose group (n ¼ 42) Low-dose group (n ¼ 41) Placebo group (n ¼ 43) p
Age (y) 77.31 ± 7.17 72.60 ± 14.52 72.37 ± 12.65 0.12
Female/male 31/11 34/7 34/9 0.72
Body weight (kg) 55.28 ± 11.64 57.32 ± 10.91 60.88 ± 13.26 0.11
Height (cm) 152.40 ± 12.46 155.00 ± 7.72 153.22 ± 13.52 0.08
BMI 24.91 ± 4.02 23.89 ± 4.55 26.06 ± 5.45 0.12
APACHE II 20.96 ± 5.05 18.75 ± 4.20 19.79 ± 4.29 0.09
Albumin (g/dL) 2.78 ± 0.70 2.58 ± 0.64 2.55 ± 0.61 0.24
Hemoglobulin (g/dL) 9.85 ± 1.56 9.58 ± 1.75 9.55 ± 1.47 0.65
Endotracheal tube size (6.5 mm or 7 mm/7.5 mm or 8.0 mm) 9/33 7/34 7/36 0.87
Intubation time (h) 176.50 ± 175.28 144.28 ± 112.23 200.14 ± 135.55 0.18
Reason for intubation 0.99
Pneumonia 12 12 10
Sepsis 5 4 5
Heart failure 5 6 6
ARDS 2 2 3
COPD 6 5 4
Asthma 0 0 1
Other 12 12 14
Glass Coma Scale 0.89
3e8 12 11 11
9e12 16 14 13
13e15 14 16 19
Data are presented as n or mean ± standard deviation.
APACHE II¼Acute Physiologic and Chronic Health Evaluation II; ARDS¼ acute respiratory distress syndrome; BMI¼ bodymass index; COPD¼ chronic obstructive pulmonary
disease.
C.-Y. Lin et al.14occurrence of PEAO is unpredictable, some authors have recom-
mended using a cuff-leak test to screen for the possibility of
PEAO7,9. According to previous studies, the risk of PEAO increases
when an absolute cuff-leak volume is less than 110e140 mL9.
However, the damage done by intubation is difﬁcult to estimate
until extubation has been performed8,23. Pre-extubation cortico-
steroid administration has been proposed to ameliorate
extubation-related laryngeal edema17.
The potential beneﬁts of systemic steroid administration for
laryngeal edema are associated with the downregulation of in-
ﬂammatory mediator24. However, the extent of the effect of pro-
phylactic steroids on airway obstruction remains a matter of
controversy. Speciﬁcally, in a previous study done by DarmonFigure 3. Patients who exhibited cuff-leak volumes of less than 110 mL at T ¼ 0
received injections at 6 hours, 12 hours, 18 hours, and 24 hours, followed by extuba-
tion. Cuff-leak tests were performed at T ¼ 0, 1 hour after each injection, and 24 hours
after the fourth injection. Data are presented as mean and standard error. Differences
in cuff-leak volumes between the placebo group and each of the dexamethasone
groups were signiﬁcant at all observation time points (p < 0.05).et al22, an 8-mg injection of dexamethasone given 1 hour before
extubation on unselected adult patients did not reduce the number
of patients requiring reintubation. Moreover, a single injection of
dexamethasone (1 mg/kg) 1 hour before extubation had no effect
on subglottic injury in a rabbit model13. Contrary to those previous
reports, there are many studies supporting the use of steroids
before extubation12,15,17e19,25. The results of our study on the efﬁ-
cacy of steroids for reducing PEAO are consistent with the results of
recent studies15,20,25,26. For example, François and colleagues25 re-
ported that four doses of 20 mg of methylprednisolone, given at 4-
hour intervals, signiﬁcantly reduced the incidence of PEAO from
22% to 3%, and reduced the incidence of reintubation from 8% to 4%.
However, the patients in this study were not restricted to patientsFigure 4. Patients who exhibited cuff-leak volumes of less than 110 mL at T ¼ 0
received injections at 6 hours, 12 hours, 18 hours, and 24 hours, followed by extuba-
tion. Cuff-leak tests were measured at T ¼ 0, 1 hour after each injection, and 24 hours
after the fourth injection. Data are presented as mean and standard error. Differences
in change of cuff-leak volumes relative to baseline tidal volume (percentage) between
each of the dexamethasone groups and the placebo group were signiﬁcant at all the
observation time points (p < 0.05).
Dexamethasone in Preventing Airway Obstruction 15at high risk for postextubation laryngeal edema. Cheng et al15 re-
ported that low CLV with less than 24% of tidal volume could be a
useful predictor of PEAO. They administered four prophylactic in-
fusions of 40 mg of methylprednisolone, given at 6-hour intervals
to high-risk adult patients with low CLV. Their results signiﬁcantly
decreased the incidence of PEAO from 30.2% to 7.1% and the rein-
tubation rate from 18.6% to 7.1%. In our previous study, we
demonstrated that low CLV of < 110 mL can be a useful predictor of
PEAO21. We found that four prophylactic infusions of 5 mg of
dexamethasone given at 6-hour intervals to high-risk adult pa-
tients with low CLV signiﬁcantly decreased the incidence of PEAO
from 27.5% to 10%. However, Tellez et al27 reported that no such
protective effect of dexamethasone exists. But in their study, pa-
tients were evaluated only for the presence of stridor requiring
epinephrine immediately after extubation, rather than assessing
airway obstruction over 24 hours following dexamethasone injec-
tion. Our present study aimed to investigate the effectiveness of
prophylactic treatment with high- versus low-dose dexamethasone
for reducing the incidence of stridor and reintubation among pa-
tients at high-risk of PEAO. The results revealed that multiple doses
of dexamethasone, regardless whether they were high or low
doses, increased absolute CLV and the change of CLV relative to
baseline tidal volume (percentage) in patients at high-risk for
PEAO. The patients in the placebo group did not show subsequent
improvement when we assessed the presence and severity of
airway obstruction. The results of our study clearly demonstrate the
efﬁcacy of dexamethasone for reducing subglottic edema in adult
patients who have been intubated for > 48 hours when the amount
of CLV was < 110 mL. Multiple factors contribute to postextubation
laryngeal edema. Lima-Rodrigues et al28 reported the increase of
inﬂammatory mediators, including tumor necrosis factor-a, inter-
leukin-1b, and interleukin-6, after intubation. Chronic inﬂamma-
tion can induce epithelial metaplasia and narrowing of the
laryngeal lumen. In a study using multiple injections of methyl-
prednisolone, Cheng et al15 reported that CLV increased signiﬁ-
cantly 2 hours after injection. The reduction of the inﬂammatory
response, as shown by decreased levels of interleukin-6 and
interleukin-8, might contribute to the lowered incidence of PEAO24.
Zhou et al29 demonstrated increased ﬁbroblast aggregation around
vocal cord epithelia and capillaries. However, ﬁbroblast prolifera-
tion and transforming growth factor-b-induced collagen synthesis
decreased signiﬁcantly after administering dexamethasone. Ac-
cording to a study by Campagnolo et al30, dexamethasone
decreased the rate of collagen synthesis 3 days after vocal cord
injury. Taken together, the effect of dexamethasone for preventing
PEAO might occur through inhibiting cytokine-induced collagen
synthesis. Baranwal et al19 recently reported that a single injection
of dexamethasone 6 hours before extubationwas not as effective as
multiple injections over a 24-hour period preceding extubation.
This might be due to the time needed for dexamethasone to exert
its inhibitory effect on cytokine-related collagen synthesis. Ac-
cording to Baranwal et al's19 study, multiple injections of low-dose
dexamethasone, e.g., 0.5 mg/kg/dose, would be sufﬁcient to pre-
vent PEAO for high-risk children.
Compared with methylprednisolone, dexamethasone has a
relatively longer potency (over 25 hours). Since extubation failure
often occurs within 48 hours after extubation, potent and long-
acting corticosteroids, such as dexamethasone, might be more
suitable than intermediate- or short-acting steroids for preventing
airway edema in patients who have been intubated for over
24 hours. Our results revealed that multiple injections of dexa-
methasone, regardless of whether they were high- or low-dose
(10 mg vs. 5 mg), progressively increased the CLV throughout the
pretreatment period 24 hours before extubation. Furthermore, the
advantageous effects may last at least 24 hours afterdiscontinuation of dexamethasone. However, administration of
dexamethasone did not affect the reintubation rate. In our study,
the patients suffering from postextubation stridor were treated
with epinephrine or noninvasive ventilation (Figure 1). This may be
one reason why the effect of dexamethasone on the reintubation
rate was not consistent with that on the incidence of post-
extubation stridor.
In conclusion, our study identiﬁes pretreatment with multiple
injections of dexamethasone is effective for reducing the frequency
of PEAO in critically ill patients experiencing prolonged intubation.
There was no signiﬁcant difference in CLV and PEAO between the
high- and low-dose (10 mg vs. 5 mg) groups. Therefore, adminis-
tering multiple low-dose dexamethasone injections (5 mg per
dose) is preferable to higher doses (10 mg per dose). Multiple in-
jections of low-dose dexamethasone should therefore be recom-
mended for prophylaxis of PEAO.References
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